S.Y. Amy Cheung

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i> -Mutated Breast and Gynecologic Cancers

Udai Banerji, Emma Dean, José Alejandro Pérez Fidalgo et al. · Clinical Cancer Research · 2017 · 146 citations · Full text

Medicine, Oncology, Pharmacology +17

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population

Nicholas C. Turner, Ashley E. Alarcon-Rozas, Anne Armstrong et al. · Annals of Oncology · 2019 · 89 citations · Full text

Medicine, Oncology, Pharmacology +16

GW231123: A Binary Black Hole Merger with Total Mass 190–265 <i>M</i> _⊙

Adrian Abac, I. Abouelfettouh, F. Acernese et al. · The Astrophysical Journal Letters · 2025 · 80 citations · Full text

Natural Sciences, Astronomy, Physics +14

Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children

Wangda Zhou, Trevor N. Johnson, Khanh Bui et al. · Clinical Pharmacology & Therapeutics · 2017 · 75 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)

John F. R. Robertson, Robert E. Coleman, Kwok‐Leung Cheung et al. · Clinical Cancer Research · 2019 · 41 citations · Full text

Medicine, Oncology, Pharmacology +17